SynthesisWorld journal of surgical oncology2025
The benefit and risk of adding immunotherapy to chemoradiotherapy as the first-line treatment for limited-stage small cell lung cancer: a meta-analysis of randomized controlled trials.
Synthesis in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLimited-stage small cell lung cancer (LS-SCLC) remains a highly aggressive malignancy with limited long-term survival despite standard chemoradiotherapy (CRT). Recently, immunotherapy has emerged as a promising adjunct to CRT, but its efficacy and safety in the first-line treatment of LS-SCLC remain uncertain. This meta-analysis of randomized controlled trials (RCTs) aimed to systematically evaluate the clinical benefits and risks of combining immunotherapy with CRT (ICRT) versus CRT alone in patients with LS-SCLC.
methodsRCTs comparing ICRT and CRT as initial therapy for LS-SCLC were retrieved from 6 databases. Data on overall survival (OS), progression-free survival (PFS), responses, and adverse events (AEs) were extracted. Pooled hazard ratios (HRs) or risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using random-effects or fixed-effects models, depending on heterogeneity.
resultsA total of 6 RCTs comprising 1036 patients were included. Compared with CRT alone, ICRT significantly improved OS (HR: 0.80 [0.67, 0.96], P = 0.02) and PFS (HR: 0.78 [0.65, 0.94], P = 0.008). Subgroup analyses of OS and PFS demonstrated that time from end of concurrent CRT to randomization < 14 day, and platinum type - carboplatin were favorable factors for ICRT group. The objective response rate (ORR), and disease control rate (DCR) were similar between the two group. However, the ICRT therapy was associated with more total/ grade 3–5 immune-related AEs (irAEs). The most common irAEs were hypothyroidism (13.64%), and pneumonitis (11.74%) in the ICRT group.
conclusionFirst-line ICRT significantly improves survival outcomes in patients with LS-SCLC compared to CRT alone, albeit with a higher risk of irAEs. PROSPERO REGISTRATION ID: CRD420251076364
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.